<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981487</url>
  </required_header>
  <id_info>
    <org_study_id>EUR-1025</org_study_id>
    <nct_id>NCT00981487</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Anti Nausea Medication With and Without Food (EUR-1025)</brief_title>
  <acronym>ODO-P8-689</acronym>
  <official_title>Single-Dose Crossover Comparative Bioavailability Study to Assess the Effect of Food on the Pharmacokinetics of Ondansetron Modified-Release Capsules (EUR-1025) in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forest Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the effect of food on a single dose of Ondansetron when taken with a&#xD;
      meal on an empty stomach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to assess the effect of food on the pharmacokinetics of a&#xD;
      single 24 mg dose of Ondansetron administered as a novel modified-release capsule formulation&#xD;
      under fed and fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of food on the pharmacokinetics of a single 24 mg dose of ondansetron administered under fed and fasting conditions</measure>
    <time_frame>1 dose on two separate days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Nausea</condition>
  <arm_group>
    <arm_group_label>Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of EUR-1025 (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The Ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of EUR-1025 (1 x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>24 mg one time</description>
    <arm_group_label>Fed</arm_group_label>
    <other_name>EUR-1025</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>24 mg, on time in the am</description>
    <arm_group_label>Fasting</arm_group_label>
    <other_name>EUR-1025</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male and female volunteers,&#xD;
&#xD;
          -  non or ex-smokers,&#xD;
&#xD;
          -  at least 21 years of age but not older than 55 years,&#xD;
&#xD;
          -  a body mass index targeted to be at least 18.5 and less than 30 kg/m2&#xD;
&#xD;
          -  healthy,&#xD;
&#xD;
          -  acceptable normal lab tests,&#xD;
&#xD;
          -  negative HIV, Hepatitis B and C,&#xD;
&#xD;
          -  a negative ethyl alcohol and drug screen,&#xD;
&#xD;
          -  normal 12 lead ECG, AND&#xD;
&#xD;
          -  negative human chorionic gonadotropin (hCG) for females.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no known hypersensitivity to ondansetron or any related products,&#xD;
&#xD;
          -  presence of significant gastrointestinal, liver or kidney disease, or any other&#xD;
             conditions known to interfere with the absorption, distribution, metabolism or&#xD;
             excretion of drugs or known to potentiate or predispose to undesired effects,&#xD;
&#xD;
          -  history of significant gastrointestinal, liver or kidney disease,&#xD;
&#xD;
          -  presence of significant cardiovascular, pulmonary, hematologic, neurological,&#xD;
             psychiatric endocrine, immunologic or dermatologic disease, suicidal tendency, history&#xD;
             of or disposition to seizures, state of confusion, clinically relevant psychiatric&#xD;
             disease, presence of significant heart disease or disorder discovered on screening&#xD;
             ECG,&#xD;
&#xD;
          -  females who are found to have a positive serum pregnancy test at screening or are&#xD;
             nursing,&#xD;
&#xD;
          -  females of childbearing potential who refuse to use an acceptable contraceptive&#xD;
             regimen from the screening visit and throughout the study,&#xD;
&#xD;
          -  maintenance therapy with any drug,&#xD;
&#xD;
          -  significant history of drug dependency or alcohol abuse (&gt; 2 units of alcohol per day,&#xD;
             intake of excessive alcohol, acute or chronic),&#xD;
&#xD;
          -  any clinically significant illness in the previous 28 days before day 1 of the study,&#xD;
&#xD;
          -  use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450&#xD;
             (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin,&#xD;
             fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP&#xD;
             enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin and&#xD;
             rifampin), in the previous 28 days before day 1 of this study,&#xD;
&#xD;
          -  volunteers who took an Investigational Product (in another clinical trial) or donated&#xD;
             50 ml or more of blood in the previous 28 days before day 1 of this study,&#xD;
&#xD;
          -  poor motivation,&#xD;
&#xD;
          -  intellectual problems likely to limit the validity of consent to participate in the&#xD;
             study or limit the ability to comply with the protocol requirements or inability to&#xD;
             cooperate adequately,&#xD;
&#xD;
          -  inability to understand and to observe the instructions of the physician,&#xD;
&#xD;
          -  donation of 500 ml or more of blood (Canadian Blood Services, Hema-Quebec, clinical&#xD;
             studies) in the previous 56 days before day 1 of this study,&#xD;
&#xD;
          -  positive urine screening of drugs or abuse,&#xD;
&#xD;
          -  any history of tuberculosis and/or prophylaxis for tuberculosis, OR&#xD;
&#xD;
          -  positive results to HIV, HBsAg, or anti-HCV tests.&#xD;
&#xD;
          -  no subject will be allowed to enroll in this study more than once.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Sicard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algorithme Pharma Inc</affiliation>
  </overall_official>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>September 21, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

